AustriaAustria

New wings for spinal research

06.03.2012

The Paracelsus Private Medical University (PMU) in Salzburg is to build a new research center for spinal cord injuries. The €70m construction tab will be picked up by Dietrich Mateschitz, the owner of Red Bull. Other partners in the project include the province of Salzburg, Salzburg’s University Hospital and the Foundation for Spinal Cord Research “Wings for Life”, which was also founded by Mateschitz. The new facility in Salzburg will focus on several research areas, including stem cells, the regeneration of nerve cells and molecular approaches to restoring injured nerve connections. Other priorities include the prevention of secondary damage after spinal cord injuries have occurred, and compensation therapies that rely on stimulation of nerves and patient rehabilitation. “This is the third largest amount that a European university has ever received from an individual,” said PMU Rector Herbert Resch. Construction will begin in the first half of 2012. It will host numerous research and teaching facilities on 8,000m2. “The close integration of basic science and clinical research on new cross-sectional and tissue regeneration will be one of the great features of the new facilities,” stressed Resch. In all, these will employ three research professors and around 40 staff.

Politics / Law

06.03.2012

The human race is at war with another species, and has been for thousands of years. Each of us in Europe swats dead dozens of the enemy every summer, and in the tropics they kill thousands of people with infectious diseases...

Tech Review

06.03.2012

The Philogen group is a specialist for therapies against cancer. Unlike other private companies, the Swiss-Italian firm has developed a rich pipeline of antibodies consisting of five different molecules being tested in 15...

Tech Review

06.03.2012

Success in the biopharmaceutical industry is mainly driven by the ability to innovate, and the continuous development of new products is crucial in that context. Shortening development times is key. The use of comprehensive...

Tech Review

06.03.2012

Zurich-based NeurImmune AG follows unconventional routes – for example, the company doesn’t rely on VC investors. And Neurimmune has also turned the drug discovery process upside down by taking its drug candidates from healthy...

Tech Review

06.03.2012

The use of bispecific antibodies recognising two different targets may allow improvement of clinical efficacy. A bispecific antibody for two growth factors that stimulate the formation of blood vessels – Ang2 (Angiopoietin-2) and...

Clinical Trial

02.03.2012

Sweden’s Karo Bio AB has been hit hard by toxicity issues with its lead compound eprotirome. The anti-cholesterol drug – which was in Phase III clinical development – proved unsafe in a long-term animal tests. The drug lead to...

Clinical Trial

01.03.2012

Inspiration Biopharmaceuticals Inc. reported on 22 February that its lead candidate drug proved successful in a clinical trial involving 12 patients who suffer from hemophilia B. The results were presented at the 5th Annual EAHAD...

Displaying results 21 to 30 out of 1983

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/2/article/new-wings-for-spinal-research.html

Product of the week

Products

Events

All Events

Current issue

All issues